SleepioRx and DaylightRx Digital CBT

Big Health is a digital mental health company whose boilerplate is datelined San Francisco in a January 2022 funding release (a USD 75 million Series C led by SoftBank Vision Fund 2). It builds digital cognitive behavioural therapy programmes for insomnia, anxiety and low mood that health systems, health plans and employers can offer.

SleepioRx is an FDA-cleared prescription CBT programme for chronic insomnia in adults, and DaylightRx is FDA-cleared for generalised anxiety disorder. Sleepio, Daylight and Spark Direct are non-prescription versions. The company states that prescription products can be billed through pharmacy benefit managers, and cites 22 randomised controlled trials and more than 500,000 patients treated.

• SleepioRx: FDA-cleared prescription digital CBT for chronic insomnia in adults 18 and over.
• DaylightRx: FDA-cleared prescription digital CBT for generalised anxiety disorder in adults 22 and over.
• Non-prescription programmes: Sleepio, Daylight and Spark Direct for sleep, worry and mood.
• Reimbursement route: billing through pharmacy benefit managers for health plans and employers.
• Evidence base: more than 100 peer-reviewed publications and 22 randomised controlled trials.
• Stakeholder offering: programmes for health systems, health plans, employers and benefits consultants.

A Vietnamese health insurer could add a digital insomnia programme to wellness riders for corporate policyholders. A large employer could pilot a self-guided sleep programme for shift workers and track outcomes.

Programmes are available instantly with no waitlist. The company reports improvements of 76% in sleep, 71% in worry and anxiety and 67% in mood, with footnoted sources. Employers and health plans can add the products through a pharmacy claim. FDA clearance and clinical guideline references support clinical governance reviews.

Digital CBT is moving from consumer apps to clinically validated, reimbursable programmes that employers and insurers fund. In Vietnam and Southeast Asia, insomnia and anxiety are common workforce complaints and insurers are looking for scalable non-drug options, though regulatory pathways differ from the US.

News page lists FDA clearance for SleepioRx (August 2024) and DaylightRx (September 2024) and a new CEO, Yael Berman (April 2024). Raised USD 75 million Series C in January 2022. Founded year not stated on fetched pages. FDA clearance applies to the US market only.